The Maternal Health market 2020 report analyses global acceptance of trends, future growth potential, key drivers, limitations, opportunities, and best practices that are taken place in market. The report also examines growth potential, market sizes and revenue forecasts (2020-2024)across different regions as well as industry verticals.
Global Maternal Health Market Overview:
A recent report by Business Industry Reports offers an in-depth analysis of global Maternal Health market from 2020 to 2024. It also edifies various sides such as key drivers, prominent developments, and various market opportunities for businesses to gain maximum profit in the projected period.
Maternal health is the health of women during pregnancy, childbirth, and the postnatal period. It includes the health care extents of family planning, preconception, prenatal, and postpartum care in order to confirm a positive and satisfying involvement in most cases and decrease maternal morbidity and mortality in other cases.
Our research report is targeting precisely on global Maternal Health market. The Global Maternal Health market is signaling an optimistic future ahead in upcoming years. The research study revolves around the global Maternal Health market and uncovers plentiful important factors that are affecting the Maternal Health market worldwide. The research report is broken down in multiple chapters such as market sizing & forecasting, market dynamics, competitive analysis, and more, which further helps the reader in earning an in-depth knowledge of the rising market of Maternal Health. The research report has also dedicated an ample of space and expertise on analyzing current market competition within the Maternal Health market. Company financials, business strategies, recent innovations, and developments are several crucial areas among other areas where our research analysts have worked hard to deliver an accurate and informative analysis of the market competition
Market Key Players
The Maternal Health market is highly competitive owing to the presence of several large and small vendors. According to the Maternal Health market analysis research report, the level of competition among the players in this market space is intense and the vendors mainly compete based on factors such as price, user-friendly interface, value-added benefits, and service benefits. To attain a competitive advantage over the other players in the Maternal Health service market, the vendors have the need to develop new ideas and technologies and they should also integrate new technologies in their product portfolio.
Johnson & Johnson
The Maternal Health market has been sub-grouped into type and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
Product Type Segmentation
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
Global Industry News:
Sanofi : Sarclisa (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
June 2, 2020 – Sarclisa (isatuximab) added to carfilzomib and dexamethasone (Sarclisa combination therapy) reduced the risk of disease progression or death by 47% (hazard ratio 0.531, 99% CI 0.318-0.889, p=0.0007, n=179) compared to standard of care carfilzomib and dexamethasone (Kd) in patients (n=123) with relapsed multiple myeloma (MM). Sarclisa combination therapy compared to Kd alone showed a treatment benefit consistent across multiple subgroups.
These results from the Phase 3 IKEMA trial follow the topline announcement on May 12, 2020 that Sarclisa combination therapy met the trial primary endpoint at the pre-planned interim analysis. Interim results will be presented during the late-breaking session of the European Hematology Association (EHA) Virtual Congress (EHA25) on June 14, 2020 and will form the basis for global regulatory submissions later this year.
“In the Phase 3 IKEMA trial, the addition of Sarclisa to carfilzomib and dexamethasone reduced the risk of disease progression or death by 47 percent compared to treatment with carfilzomib and dexamethasone alone,” said Philippe Moreau, M.D., Department of Hematology, University Hospital of Nantes, France. “These results suggest the potential of Sarclisa to become a new standard of care in the relapsed multiple myeloma setting.”
While median progression free survival (PFS), defined as time to disease progression or death, for Kd was 19.15 months, the median PFS for patients receiving Sarclisa combination therapy had not been reached at the time of the pre-planned interim analysis. The safety and tolerability of Sarclisa observed in this trial was consistent with the observed safety profile of Sarclisa in other clinical trials, with no new safety signals observed.
“This is the second Phase 3 trial to demonstrate superior results with Sarclisa combination therapy over a standard of care regimen, adding to the growing body of evidence that our anti-CD38 monoclonal antibody has the potential to make a meaningful difference for patients,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. “We believe Sarclisa has the potential to become the anti-CD38 of choice for the treatment of multiple myeloma. We look forward to seeing the results from future clinical trials to understand the impact of Sarclisa in earlier stages of disease.”
Key Points Covered :
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Major Points in Table of Contents:
Section 1 Maternal Health Product Definition
Section 2 Global Maternal Health Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Maternal Health Shipments
2.2 Global Manufacturer Maternal Health Business Revenue
2.3 Global Maternal Health Market Overview
2.4 COVID-19 Impact on Maternal Health Industry
Section 3 Manufacturer Maternal Health Business Introduction
3.1 Ageil Therapeutics Maternal Health Business Introduction
3.1.1 Ageil Therapeutics Maternal Health Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 Ageil Therapeutics Maternal Health Business Distribution by Region
3.1.3 Ageil Therapeutics Interview Record
3.1.4 Ageil Therapeutics Maternal Health Business Profile
3.1.5 Ageil Therapeutics Maternal Health Product Specification
3.2 Fuji Latex Maternal Health Business Introduction
3.2.1 Fuji Latex Maternal Health Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 Fuji Latex Maternal Health Business Distribution by Region
3.2.3 Interview Record
3.2.4 Fuji Latex Maternal Health Business Overview
3.2.5 Fuji Latex Maternal Health Product Specification
3.3 Johnson & Johnson Maternal Health Business Introduction
3.3.1 Johnson & Johnson Maternal Health Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Johnson & Johnson Maternal Health Business Distribution by Region
3.3.3 Interview Record
3.3.4 Johnson & Johnson Maternal Health Business Overview
3.3.5 Johnson & Johnson Maternal Health Product Specification
3.4 Okamoto Industries Maternal Health Business Introduction
3.5 Reckitt Benckiser Maternal Health Business Introduction
3.6 Sanofi Maternal Health Business Introduction